TY - JOUR
T1 - Hepatitis C action plan for Scotland
T2 - phase II (May 2008 - March 2011)
AU - Goldberg, David
AU - Brown, G.
AU - Hutchinson, Sharon
AU - Dillon, J.
AU - Taylor, A.
AU - Howie, G.
AU - Ahmed, S.
AU - Roy, Kirsty
AU - King, M.
PY - 2008/5/22
Y1 - 2008/5/22
N2 - In 2004, the Scottish Government recognised that 'Hepatitis C is one of the most serious and significant public health risks of our generation' [1]. By December 2006, Health Protection Scotland (HPS) estimated that 50,000 people in Scotland had been infected with the hepatitis C virus (HCV) and that 38,000 were chronic carriers (Figure 1) [2]. Following an extensive consultation in 2005, the Health Minister and Chief Medical Officer launched Scotland's' Action Plan for Hepatitis C' in September 2006 [3]. Its aims are to prevent the spread of hepatitis C, particularly among intravenous drug users (IDUs), to diagnose hepatitis C-infected people, particularly those who would most benefit from treatment; and to ensure that those infected receive optimal treatment, care and support. The plan is a two-phased one. Phase I, undertaken during September 2006 to March 2008, involved increasing awareness about hepatitis C among professionals and gathering evidence through numerous surveys and other investigations to inform proposals for the development of hepatitis C services during Phase II (2008-2011)[4]. This paper presents the key findings of the evidence gathering exercise, recommended actions stemming from the evidence and funding associated with the actions.
AB - In 2004, the Scottish Government recognised that 'Hepatitis C is one of the most serious and significant public health risks of our generation' [1]. By December 2006, Health Protection Scotland (HPS) estimated that 50,000 people in Scotland had been infected with the hepatitis C virus (HCV) and that 38,000 were chronic carriers (Figure 1) [2]. Following an extensive consultation in 2005, the Health Minister and Chief Medical Officer launched Scotland's' Action Plan for Hepatitis C' in September 2006 [3]. Its aims are to prevent the spread of hepatitis C, particularly among intravenous drug users (IDUs), to diagnose hepatitis C-infected people, particularly those who would most benefit from treatment; and to ensure that those infected receive optimal treatment, care and support. The plan is a two-phased one. Phase I, undertaken during September 2006 to March 2008, involved increasing awareness about hepatitis C among professionals and gathering evidence through numerous surveys and other investigations to inform proposals for the development of hepatitis C services during Phase II (2008-2011)[4]. This paper presents the key findings of the evidence gathering exercise, recommended actions stemming from the evidence and funding associated with the actions.
KW - hepatitis c
KW - drugs
KW - medical research
KW - statistics
KW - mathematics
UR - http://eurosurveillance.org/
UR - http://eurosurveillance.org/ViewArticle.aspx?ArticleId=18876
M3 - Article
SN - 1560-7917
VL - 13
SP - 1
EP - 2
JO - Eurosurveillance
JF - Eurosurveillance
IS - 4-6
ER -